Original Article

Implementation of a CIWA-Ar Alcohol Withdrawal Protocol in a Veterans Hospital

Authors: Courtney Waye, PharmD, Mark Wong, PharmD, Shuko Lee, MS

Abstract

Objectives: The South Texas Veterans Health Care System (STVHCS) implemented a Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)–based alcohol-withdrawal protocol in June 2013. The aim of this study was to determine the efficacy and safety of the new protocol. The primary objective was the evaluation of whether implementation of the CIWA-Ar alcohol-withdrawal protocol decreased the average length of hospital stay for patients admitted with alcohol withdrawal syndrome (AWS) as compared with treatment before the introduction of the protocol. Secondary endpoints evaluated benzodiazepine (BZD)-prescribing practices, use of adjunctive medications for AWS, and safety outcomes.

Methods: We reviewed 748 admissions with documented AWS or alcohol-related diagnoses during the study periods of July 2012 to December 2012 (preprotocol) and July 2013 to December 2013 (postprotocol). Patients in the preprotocol group needed to have a scheduled dose of a BZD in the electronic medical record, and those assigned to the postprotocol group needed to have at least one documented CIWA-Ar note in their electronic medical record. Exclusion criteria included prior conditions that interfered with accurate treatment of alcohol withdrawal.

Results:
There were no statistical differences in baseline characteristics between groups. No difference was found in the primary endpoint of length of stay when comparing hospitalizations pre- and postprotocol implementation (3.84 ± 2.31 days vs 3.82 ± 2.7 days; P = 0.667). There was no statistical significance in total cumulative dose of BZD, daily dose of BZD, or duration of BZD use when compared pre- and postprotocol. No safety events requiring further intervention occurred.

Conclusions: Implementation of a CIWA-Ar protocol at our institution did not result in a decreased duration of hospital stay; however, a decline in prescribing fixed-schedule BZDs was documented.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. National Institute on Alcohol Abuse and Alcoholism. Twelve month prevalence and population estimates of DSM-IV alcohol dependence by age, sex, and race-ethnicity; United States. 2001-2002. http://www.niaaa.nih.gov/Resources/DatabaseResources/QuickFacts/AlcoholDependence/abusdep2.htm. Accessed August 1, 2013.
 
2. Smothers BA, Yahr HT, Ruhl CE. Detection of alcohol use disorders in general-hospital admissions in the United States. Arch Intern Med 2004;164:749-756.
 
3. Etherington JM. Emergency management of acute alcohol problems. Part 1: uncomplicated withdrawal. Can Fam Physician 1996;42:2186-2190.
 
4. Vincent WR, Smith KM, Lewis DA, et al. Review of alcohol withdrawal in the hospitalized patient: diagnosis and assessment. Orthopedics 2007;30:358-361.
 
5. DeBellis R, Smith BS, Choi S, et al. Management of delirium tremens. J Intensive Care Med 2005;20:164-173.
 
6. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353-1357.
 
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 2000.
 
8. Mihic SJ, Ye Q, Wick MJ, et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997;389:385-389.
 
9. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152:332-340.
 
10. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analyis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997;278:144-151.
 
11. Ng K, Dahri K, Chow I, et al. Evaluation of an alcohol withdrawal protocol and a preprinted order set at a tertiary care hospital. Can J Hosp Pharm 2011;64:436-445.
 
12. Reoux JP, Miller K. Routine hospital alcohol detoxification practice compared to symptom triggered management with an objective withdrawal scale (CIWA-Ar). Am J Addict 2000;9:135-144.
 
13. DeCarolis DD, Rice KL, Ho L, et al. Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit. Pharmacotherapy 2007;27:510-518.
 
14. Damin-Ross R. Acute Alcohol Detoxification Process Action Team. Implementation of the Clnical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) Durham, NC: Durham VA Medical Center; 2012.
 
15. Bostwick JM, Lapid MI. False positives on the clinical institute withdrawal assessment for alcohol-revised: is this scale appropriate for use in the medically ill? Psychosomatics 2004;45:256-261.
 
16. Wetterling T, Kanitz RD, Besters B, et al. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol 1997;32:753-760.